ASH 2023 Oral Presentation: Durability of Hematocrit Control in Polycythemia Vera With the First-in-Class Hepcidin Mimetic Rusfertide: Two-Year Follow up Results From the REVIVE Study

December 11, 2023

DOWNLOAD PRESENTATION